Vericel (NASDAQ:VCEL) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Vericel (NASDAQ:VCEL) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21, Zacks reports. The firm had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS.

Here are the key takeaways from Vericel’s conference call:

• Vericel reported third-quarter revenue of $85.4 million, up 26%, and raised 2026 revenue guidance to $344 million–$346 million after results exceeded expectations. The company also raised adjusted EBITDA margin guidance to approximately 28%.
• MACI revenue grew 21% to a record $67.4 million, with records for biopsies, implants, and participating surgeons; October also brought the strongest biopsy month since launch. Management cited sales-force expansion, deeper surgeon engagement, and MACI Arthro adoption as growth drivers, while noting that biopsies convert to procedures over time.
• Burn-care revenue reached a record $18 million, up 52%, with record quarterly revenue for both Epicel and commercial NexoBrid. Management attributed Epicel’s strength mainly to commercial execution, while acknowledging that burn-care results can be variable and that the number of severe burns is outside the company’s control.
• Profitability and cash generation strengthened: adjusted EBITDA rose 48% to $25.2 million, free cash flow was $16 million, and the company ended the quarter with $236 million in cash and investments and no debt. Vericel said it remains on track with its longer-term targets, while continuing investments in growth and exploring both share repurchases and business development.

Vericel Stock Up 13.9%

Vericel stock traded up $6.30 during trading on Thursday, reaching $51.78. The stock had a trading volume of 2,682,362 shares, compared to its average volume of 594,165. Vericel has a 52-week low of $28.95 and a 52-week high of $55.60. The stock has a market cap of $2.65 billion, a PE ratio of 110.17 and a beta of 1.08. The business has a 50 day moving average price of $40.74 and a 200 day moving average price of $38.80.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported third-quarter revenue of $85.4 million, up 26% year over year and above the roughly $78.0 million consensus. EPS of $0.27 also beat estimates, while net income rose 179% to $14.2 million. The company cited record MACI sales in coverage of the results. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its 2026 revenue outlook to $344 million–$346 million, above analyst expectations of about $336 million, and set adjusted EBITDA margin guidance at 28%. The higher forecast reinforces expectations for continued growth. 2026 revenue outlook
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a concern that could temper enthusiasm after the results-driven advance. Vericel valuation commentary

Analyst Upgrades and Downgrades

Several equities analysts have commented on VCEL shares. TD Cowen boosted their price target on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Vericel in a research note on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $60.00 price target on Vericel in a report on Thursday, July 30th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.20.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.